acetyl-CoA

Biomarker1 paper1 finding

Human trial1

Interventions

1

Tofogliflozin

upin humans1Moderate certainty

1 study

Tofogliflozin increases acetyl-CoA in humans.
Human trialtype 2 diabetes and biopsy-confirmed MASLDliver48 weeks
Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study · Biochemistry and biophysics reports · 14 Sep 2026

Tofogliflozin →

Latest

6

GenesReview26 Sep

The Epigenetic Aging-Cancer Continuum: Biomarkers, Metabolism, and Therapy

NAD+ metabolism

Biochemistry and Biophysics ReportsHuman trial23 Sep

Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study

Free Radical Biology & MedicineAnimals17 Sep

Brown adipocyte Acss1 restoration ameliorates redox-metabolic dysfunction and systemic metabolic decline during aging

Nihon Yakurigaku Zasshi Folia Pharmacologica JaponicaReview3 Sep

[Pharmacological properties and clinical efficacy of bempedoic acid (NEXLETOL® tablets 180 mg) for the treatment of hypercholesterolemia]

Hypercholesterolemia

Neuropharmacology and TherapyReview22 Aug

Polyamine Metabolism in Brain Health and Disease

GSA 2025 AbstractCells3 Jan

Exploring Acetyl-CoA-Mediated Beta-Hydroxybutyrate Enrichment in Yeast: A Mechanistic Link to Longevity